Asia-Pacific DTC Laboratory Testing Market (2025-2032)
The Asia-Pacific DTC Laboratory Testing Market is projected to reach $1.58 billion by 2032, at a CAGR of 12.8% from 2025 to 2032.
- Published
- Jan 2025
- Pages
- 185
- Format
- PDF + Excel
- Report ID
- MRHC - 104990
- Base year
- 2024
- 2032 · FORECAST
- $1.58B
- 2032
- $1.58B
- CAGR 2025–2032
- 12.8%
2024 baseline · 2025–2032 forecast at 12.8% CAGR · hover a bar for the value
Key highlights
The Asia-Pacific DTC Laboratory Testing Market is projected to reach $1.58 billion by 2032, at a CAGR of 12.8% from 2025 to 2032.
The genetic testing segment is expected to account for the largest share of the market.
The blood segment is expected to account for the largest share of the market.
The growth of the Asia-Pacific DTC Laboratory testing market is driven by several factors, including the rising incidence of chronic diseases and sexually transmitted diseases, high disposable income, increased consumer awareness, increasing awareness about personal health management, benefits of DTC laboratory testing such as high convenience, affordability, and accessibility, increasing prevalence of chronic and infectious diseases, the increasing cost of healthcare, and the rising elderly population.
Report summary
| Particulars | Details |
|---|---|
| Base Year | 2024 |
| Estimated Year | 2025 |
| Forecast Period | 2025–2032 |
| Market Size (2032) | USD 1.58 billion |
| CAGR (2025–2032) | 12.8% |
| Format | PDF, Excel & Cloud Portal · 185 pages |
| Segments Covered | By Application: Genetic Testing Ancestry/Genealogy, Disease Risk Assessment Cancer, Cardiovascular Diseases, Neurological Diseases, Other Diseases · By Sample Type: Blood, Saliva, Urine, Other Samples |
| Countries Covered | Asia-Pacific (RoAPAC) |
| Key Companies | Metropolis Healthcare Limited, SRL Limited, Hirotsu Bio Science, Mapmygenome India Limited, Genesis Healthcare Co., Augmentum Diagnostics, Apollo Health and Lifestyle Limited, WeGene, GeseDNATechnology LLP, Laboratory Corporation of America Holdings (U.S.), LetsG |
Report overview
Segments covered: application, sample type. Regions: Asia-Pacific.
Direct-to-consumer or DTC tests are the ones that are self-ordered by consumers without the involvement of their healthcare providers. The sample that is collected from the consumer is processed at a laboratory, and the results are then sent directly to the consumer.
The growth of the Asia-Pacific DTC Laboratory testing market is driven by several factors, including the rising incidence of chronic diseases and sexually transmitted diseases, high disposable income, increased consumer awareness, increasing awareness about personal health management, benefits of DTC laboratory testing such as high convenience, affordability, and accessibility, increasing prevalence of chronic and infectious diseases, the increasing cost of healthcare, and the rising elderly population. Factors such as the growing adoption of telehealth, expansion in emerging economies, and the increasing penetration of pharmacogenomic testing in DTC laboratory testing are a few of the opportunities that would help grow the market in the future. Genetic data privacy concerns, misinterpretation of test results, and lack of professional medical counseling could be considered challenges for the Asia-Pacific DTC Laboratory testing market. However, sample integrity and interference issues, regulatory concerns, lack of reimbursement, and the limited test portfolio compared to conventional laboratory testing restrain the growth of the market.
Report infographic
Market dynamics
1 factors across 1 forceIncreasing Population Coupled with Rising Chronic Diseases
The rising prevalence of chronic & infectious diseases is expected to drive the demand for DTC laboratory testing. Many DTC laboratory testing companies are offering tests for diagnosing infectious diseases and monitoring chronic diseases. China has the world’s largest population, with about 1.45 billion people as of 2025. The sheer large population of the country leads to high demand for various healthcare services, including DTC Laboratory services. The geriatric population is also estimated to reach 225 million in 2032 from 170 million in 2020. The elderly population is more prone to chronic and infectious diseases due to immune dysfunction, malnutrition, and aging-related physiological changes. The rising disease burden can directly affect a country’s social and economic status. Thus, it is necessary to adopt early diagnostic procedures to minimize the burden of these diseases. The large population, the rise in the geriatric population, and the rising prevalence of diseases have led to increased demand for DTC Laboratory testing. Thus, the advantages of DTC lab testing, such as discretion & confidentiality and the increased prevalence of sexually transmitted diseases, are expected to drive the demand for DTC lab testing.
Table of contents
10 chapters · 95 sections · 185 pages · click to expandSegmental analysis
| Segment | Largest share (2025) | Fastest growth (2025–2032) |
|---|---|---|
| By All the Application | Genetic Testing | — |
| By Sample Type | Blood | — |
By All the Application
- The genetic testing segment is expected to account for the largest share of the market.
- DTC genetic tests are those that are provided directly to consumers without involving a healthcare provider.
- This testing generally offers a wide range of genetic tests that can be helpful to provide consumers with information about their ancestry, health risks, and traits.
- This segment is driven by factors such as increasing awareness regarding personal health management, high curiosity about self-ancestry, strong marketing strategies by the companies, rising prevalence of various genetic & chronic diseases, and high demand for personalized testing services.
By Sample Type
- The blood segment is expected to account for the largest share of the market.
- The blood sample is collected from consumers to test conditions such as diabetes, routine clinical testing, thyroid function, and sexually transmitted disease testing, among others, in order to gain insight into how the organs are functioning.
- Blood samples are collected using a lancet or a needle that is present in the kit provided to carry out the test.
- This segment is driven by factors such as a large variety of available tests using blood samples, increasing prevalence of various chronic diseases, and increasing consumer awareness regarding the monitoring of chronic diseases.
Geographic analysis
Asia-Pacific
The growth of the Asia-Pacific DTC Laboratory testing market is driven by several factors, including the rising incidence of chronic diseases and sexually transmitted diseases, high disposable income, increased consumer awareness, increasing awareness about personal health management, benefits of DTC laboratory testing such as high convenience, affordability, and accessibility, increasing prevalence of chronic and infectious diseases, the increasing cost of healthcare, and the rising elderly population.
Competitive landscape
- Metropolis Healthcare Limited · India
- SRL Limited · India
- Hirotsu Bio Science · Japan
- Mapmygenome India Limited · India
- Genesis Healthcare Co. · Japan
- Augmentum Diagnostics · India
- Apollo Health and Lifestyle Limited · India
- WeGene · China
- GeseDNATechnology LLP · China
- Laboratory Corporation of America Holdings (U.S.)
- LetsG
Frequently asked questions
This market study covers the market sizes & forecasts of the direct-to-consumer (DTC) laboratory testing market in Asia-Pacific based on application, sample type, and geography. This market study also provides the value analysis of various segments and subsegments of the Asia-Pacific DTC laboratory testing market at country levels.
Cite this report
Meticulous Research. (2025). Asia-Pacific DTC Laboratory Testing Market - Opportunity Analysis and Industry Forecast (2025-2032) (Report No. MRHC - 104990). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/asia-pacific-dtc-laboratory-testing-market-5673